Elcelyx
Edit

Elcelyx

https://www.elcelyx.com/
Last activity: 01.10.2015
Active - Reference to HugeDomains
Categories: PlatformTechnology
Elcelyx was founded in 2010 to advance Gut Sensory Modulation (GSM) technology, based on the elucidation that enteroendocrine cells located in the lining of the lower gut can be modulated locally to elicit systemic physiological and pharmacological effects. This discovery affords a potentially safety-advantaged platform to develop novel therapies as well as re-position existing therapies to meet serious unmet needs.
http://www.Elcelyx.com
Mentions
15
Location: United States, California, San Diego
Employees: 11-50
Total raised: $64M
Founded date: 2009

Investors 2

Funding Rounds 3

DateSeriesAmountInvestors
01.10.2015Series E$40M-
14.02.2013Series C$20M-
13.08.2012Series B$4M-

Mentions in press and media 15

DateTitleDescription
01.10.2015Elcelyx raises $40M to push its reinvented diabetes drug to Phase IIIElcelyx Therapeutics, developing a long-acting formulation of the old diabetes treatment metformin, closed a $40 million funding round to advance its lead therapy toward pivotal trials. Metformin, introduced more than 50 years ago, is consi...
01.10.2015Daily funding roundup - October 1, 2015General Assembly raised $70M; Neon Therapeutics secured $55M; Dolly landed $8M Social Finance (SoFi for short), a lending startup has raised a monster round of funding, taking $1 billion from SoftBank, with existing Third Point Ventures and...
01.10.2015 Elcelyx Therapeutics Gets $40M For Diabetes Treatment San Diego-based Elcelyx Therapeutics, which is developing treatents for type 2 diabetes, said this morning that it has raised $40M in a Series E funding round. The funding came from new investor Sailing Capital, Clough Capital Partners, as ...
01.10.2015Elcelyx Therapeutics Raises $40M in Series E FinancingElcelyx Therapeutics, a San Diego, CA-based developer of pharmaceutical products for diabetes, raised $40m in Series E financing. The round was led by Sailing Capital, with participation from Clough Capital Partners, L.P., and existing inve...
24.08.2015Elcelyx: Taking the GI, kidney distress out of diabetes drug metforminElcelyx has formulated a delayed release form of the the drug, which is meant keep diabetic blood sugars down without adding the stomach upset – and keeping the kidney functioning safely. It just released data from Phase 2 testing that it’s...
14.02.2013Elcelyx Therapeutics Closes $20M Series C FinancingElcelyx Therapeutics, a San Diego, CA-based developer of products for weight management and obesity-related metabolic disorders, closed a $20m Series C financing. The round was led by GSM Fund LLC, with participation from existing investors...
14.02.2013Elcelyx Therapeutics Completes $20M Series C SAN DIEGO, CA, Elcelyx Therapeutics announced today the closing of a $20 million Series C financing to fund development of product candidates NewMet for Type 2 diabetes and Lovidia, an over-the-counter weight loss product. The financing w...
14.02.2013Elcelyx Therapeutics Closes $20M Series C Financing RoundSan Diego-based Elcelyx Therapeutics Inc. closed a $20 million Series C financing round to develop two diabetes-related products. The financing was led by San Diego’s GSM Fund LLC, a fund dedicated to this single investment. It is managed b...
13.08.2012Fundraising: Weight loss and diabetes treatment firm raises $4M of $7M extension of series B roundLocation: San Diego, California. Solution/product: Lovidia is a dietary supplement that helps in weight loss; NewMet treats type 2 diabetes. Money raised: $4 million of a $7 million extension round; filings show it has raised $20 million to...
13.08.2012 Elcelyx Therapeutics Adds $4M San Diego-based Elcelyx Therapeutics, a developer of biopharmaceuticals aimed at both the weight loss and diabetes area, said this morning that it has raised $4M of a $7M extension of its Series B equity funding round. The new funding came ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In